Library Item Posts on Medivizor
Navigation Menu

Library Item Posts on Medivizor

How useful is progestogen for the prevention of recurrent miscarriage?

Posted by on Nov 18, 2018 in Infertility | 0 comments

In a nutshell This study investigated the use of progestogen (PTG) to prevent miscarriage in women with recurrent miscarriages (RM). They found that PTG reduces the chance of miscarriage in following pregnancies. Some background Pregnancy loss or miscarriage affects many women. Some women may experience several miscarriages, or recurrent miscarriages...

Read More

Outcomes of reduced-intensity conditioning before alloSCT for relapsed or refractory Hodgkin lymphoma

Posted by on Nov 18, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the outcomes of reduced-intensity conditioning followed by allogeneic stem cell transplantation (alloSCT) in patients with Hodgkin’s lymphoma (HL). This study concluded that this treatment improved survival outcomes in these patients. Some background AlloSCT is an effective therapy for patients with HL who...

Read More

Reducing LDL cholesterol may prevent heart disease in patient with type 2 diabetes

Posted by on Nov 17, 2018 in Diabetes mellitus | 0 comments

In a nutshell This study aimed to see if using statins to lower LDL (low-density lipoprotein) cholesterol in patients with type 2 diabetes (T2D) with high cholesterol and eye damage reduced the risk for cardiovascular (CV) events such as heart attacks, strokes, kidney disease, and deaths. The main finding of the study was that lowering LDL...

Read More

How safe and effective is dapagliflozin add-on in type 1 diabetes?

Posted by on Nov 17, 2018 in Diabetes mellitus | 0 comments

In a nutshell The aim of the study was to investigate how safe and effective dapagliflozin (Forxiga, Farxiga) is as an add-on therapy to insulin in type 1 diabetes. The main finding of the study was that dapagliflozin led to better blood sugar control and weight loss but increased the risk of complications in these patients. Some background The aim of...

Read More

Perindopril and amlodipine – can this combination prevent organ damage in ischemic heart disease?

Posted by on Nov 17, 2018 in Coronary artery disease | 0 comments

In a nutshell This study investigated the effects of the drug combination perindopril and amlodipine (PEAM) on organ damage in patients with hypertension and ischemic heart disease (IHD). They found that PEAM was effective in reducing blood pressure and organ damage in these patients. Some background Hypertension or high blood pressure (BP) is a...

Read More

Perindopril and amlodipine – can this combination prevent organ damage in hypertension?

Posted by on Nov 17, 2018 in Hypertension | 0 comments

In a nutshell This study investigated the effects of the drug combination perindopril and amlodipine (PEAM) on organ damage in patients with hypertension with and without ischemic heart disease (IHD). They found that PEAM was effective in reducing blood pressure and organ damage in these patients. Some background Hypertension or high blood...

Read More

Levodopa in the treatment to impulse control disorder in patients with Parkinson’s disease

Posted by on Nov 17, 2018 in Parkinson's Disease | 0 comments

In a nutshell This study investigated whether abnormal behavior in patients with Parkinson’s disease (PD) and impulse control disorder (ICD) was affected by a change in drug treatment. Researchers suggested that switching from dopamine agonists to levodopa/carbidopa improved ICD outcomes and daily activities. Some background ICD is present in...

Read More

Adding anthracyclines or carboplatin to standard treatment of breast cancer

Posted by on Nov 17, 2018 in Breast cancer | 0 comments

In a nutshell This study wanted to find out which medication is better for treating HER-2 positive breast cancer, a class of medicines called anthracyclines plus trastuzmab (Herceptin) and pertuzmab (Perjeta), or carboplatin (Paraplatin) plus trastuzmab and pertuzmab. The study found that both medications worked equally as well as each other, but the...

Read More

Comparing two hormone therapy drugs in men with advanced, non-metastatic prostate cancer

Posted by on Nov 17, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to compare two hormone therapies, gonadotropin-releasing hormone (GnRH) agonists and anti-androgen therapy (AA) in men with advanced, non-metastatic prostate cancer. This study found that the two therapies have similar outcomes, but by starting with AA treatment may reduce side effects associated with GnRH...

Read More

How do we manage resistant hypertension: recommendations from the American Heart Association (AHA)?

Posted by on Nov 17, 2018 in Hypertension | 0 comments

In a nutshell This study reviewed the diagnosis and treatment of resistant hypertension. Some background Hypertension or high blood pressure (BP) is a common condition. Patients with hypertension have a higher risk of cardiovascular (heart and circulatory system) disease. There is also an increased risk of stroke, disability and death. Hypertension...

Read More

Continuing versus stopping sitagliptin when starting insulin glargine therapy in type 2 diabetes

Posted by on Nov 17, 2018 in Diabetes mellitus | 0 comments

In a nutshell This study aimed to compare the effects of continuing versus stopping sitagliptin (Januvia) when starting insulin glargine (Lantus) therapy in patients with type 2 diabetes. The main finding of the study was that those who continued sitagliptin after starting insulin glargine had better blood glucose control without an increase in side...

Read More